A Light-Inducible Split-dCas9 System for Inhibiting the Progression of Bladder Cancer Cells by Activating p53 and E-cadherin
Related Experiment Video
Updated: Nov 20, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Xinbo Huang1, Qun Zhou2, Mingxia Wang1
1Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen-Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China.
Abstract:
Optogenetic systems have been increasingly investigated in the field of biomedicine. Previous studies had found the inhibitory effect of the light-inducible genetic circuits on cancer cell growth. In our study, we applied an AND logic gates to the light-inducible genetic circuits to inhibit the cancer cells more specifically. The circuit would only be activated in the presence of both the human telomerase reverse transcriptase (hTERT) and the human uroplakin II (hUPII) promoter. The activated logic gate led to the expression of the p53 or E-cadherin protein, which could inhibit the biological function of tumor cells. In addition, we split the dCas9 protein to reduce the size of the synthetic circuit compared to the full-length dCas9. This light-inducible system provides a potential therapeutic strategy for future bladder cancer.
Insights
This study developed a novel light-inducible optogenetic system using AND logic gates to specifically inhibit bladder cancer cells. The system targets cancer cells expressing both hTERT and hUPII promoters, offering a potential new therapy.
Area of Science:
- Biomedical Engineering
- Synthetic Biology
- Oncology
Background:
- Optogenetic systems are being explored for biomedical applications, with prior research showing their potential to inhibit cancer cell growth.
- Existing light-inducible genetic circuits offer a basis for cancer therapy, but specificity remains a challenge.
Purpose of the Study:
- To engineer a more specific light-inducible genetic circuit for inhibiting cancer cell growth using an AND logic gate.
- To investigate the therapeutic potential of this system for bladder cancer treatment.
Main Methods:
- Designed a synthetic genetic circuit incorporating an AND logic gate activated by two specific promoters: human telomerase reverse transcriptase (hTERT) and human uroplakin II (hUPII).
- Engineered the circuit for light-inducible activation, leading to the expression of tumor-inhibitory proteins (p53 or E-cadherin).
- Modified the dCas9 protein by splitting it to reduce the overall size of the synthetic circuit for improved delivery or efficiency.
Main Results:
- The AND logic gate system demonstrated specific activation only in cells expressing both hTERT and hUPII promoters.
- Activation of the logic gate resulted in the expression of p53 or E-cadherin, proteins known to inhibit tumor cell function.
- The split dCas9 approach successfully reduced the size of the synthetic optogenetic circuit.
Conclusions:
- The developed light-inducible AND logic gate system offers enhanced specificity for targeting cancer cells.
- This optogenetic approach, utilizing specific cancer biomarkers and tumor-suppressive gene expression, presents a promising therapeutic strategy for bladder cancer.
- Further development of this system could lead to novel, targeted cancer therapies.
